Manyu Li1, Qiuning Bu2, Wanyun Gong1, Haomin Li1, Lin Wang1, Shuangshuang Li1, Siddharth Sridhar3, Patrick Cy Woo3, Ling Wang1. 1. Department of Microbiology and Center of Infectious Disease, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, PR China. 2. Department of Clinical Laboratory, Qinhuangdao First Hospital, Hebei, PR China. 3. Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, ROC.
Abstract
Background and aims: The aim of this study was to investigate the positive rate of hepatitis E virus (HEV) infection and the possible adverse outcomes in pregnant women of Qinhuangdao, China. Methods: Serum samples of 946 pregnant women were collected from July 2017 to October 2017 in Qinhuangdao First Hospital. All samples were tested for anti-HEV IgM and IgG antibodies by enzyme-linked immunosorbent assay (ELISA). HEV RNA was tested by reverse transcription-nested polymerase chain reaction (RT-nPCR) and the PCR products were sequenced. Results: Of the 946 samples, the positive rate of anti-HEV IgM (15/365, 4.11%), anti-HEV IgG (74/365, 20.27%) and both anti-HEV IgM and IgG (12/365, 3.29%) were significantly higher (p < .05) in third trimester pregnant women than in the first (3/288, 1.04%; 36/288, 12.5%; 4/288, 1.39%), and second trimesters (6/293, 2.05%; 29/293, 9.90%; 2/293, 0.68%). The average alanine transaminase (ALT) level (34.49 ± 10.15) and the incidence of adverse pregnancy outcomes (13/18, 72.22%) in the both anti-HEV IgM and IgG positive group were significantly higher than other groups (p < .05). HEV RNA was detected in 1/181 (0.55%) of pregnant women with a history of HEV infection and the detected HEV strain belonged to subgenotype 4a.Conclusions: This study showed that pregnant women who have HEV infection can possibly lead to adverse pregnancy outcomes.
Background and aims: The aim of this study was to investigate the positive rate of hepatitis E virus (HEV) infection and the possible adverse outcomes in pregnant women of Qinhuangdao, China. Methods: Serum samples of 946 pregnant women were collected from July 2017 to October 2017 in Qinhuangdao First Hospital. All samples were tested for anti-HEV IgM and IgG antibodies by enzyme-linked immunosorbent assay (ELISA). HEV RNA was tested by reverse transcription-nested polymerase chain reaction (RT-nPCR) and the PCR products were sequenced. Results: Of the 946 samples, the positive rate of anti-HEV IgM (15/365, 4.11%), anti-HEV IgG (74/365, 20.27%) and both anti-HEV IgM and IgG (12/365, 3.29%) were significantly higher (p < .05) in third trimester pregnant women than in the first (3/288, 1.04%; 36/288, 12.5%; 4/288, 1.39%), and second trimesters (6/293, 2.05%; 29/293, 9.90%; 2/293, 0.68%). The average alanine transaminase (ALT) level (34.49 ± 10.15) and the incidence of adverse pregnancy outcomes (13/18, 72.22%) in the both anti-HEV IgM and IgG positive group were significantly higher than other groups (p < .05). HEV RNA was detected in 1/181 (0.55%) of pregnant women with a history of HEVinfection and the detected HEV strain belonged to subgenotype 4a.Conclusions: This study showed that pregnant women who have HEVinfection can possibly lead to adverse pregnancy outcomes.
Authors: Tauseef Ahmad; Saima Nasir; Taha Hussein Musa; Saif Aldeen S AlRyalat; Muhammad Khan; Jin Hui Journal: Hum Vaccin Immunother Date: 2020-08-05 Impact factor: 3.452
Authors: Thomas Horvatits; Julian Schulze Zur Wiesch; Marc Lütgehetmann; Ansgar W Lohse; Sven Pischke Journal: Viruses Date: 2019-07-05 Impact factor: 5.048